Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complet if Known	
Application Number	09/853,753
Filing Date	May 14, 2001
First Named Inventor	B ch-Hansen
Group Art Unit	not assigned
Examiner Name	not assigned
Attorney Docket Number	45499.2

#1/2 D.J 1/22/02

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
OC	AA	Loss of Function Mutations in a Calcium-Channel α_1 subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness - Paper by Bech-Hansen, et al. July, 1998.	
OC	AB	Mutations in NYX, encoding the leucine-rich proteoglycan nyctalopin, cause X-linked incomplete cogenital stationary night blindness - Paper by Bech-Hansen et al. November, 2000.	
OC	AC	Evidence for Genetic Heterogeneity in X-linked Cogenital Stationary Night Blindness - Paper by Bech-Hansen, et al. - published April 7, 1998.	
OC	AD	Leucine-Rich Repeat Glycoproteins of the Extracellular Matrix - Paper by Hocking, et al. accepted January 29, 1998.	

Examiner Signature		Date Considered	03/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.